DividendChannel.com
BMY Dividend History & Description — Bristol Myers Squibb Co.

Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Co.'s pharmaceutical products include chemically-synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor T-cell therapies. Co.'s primary product includes Eliquis® - Eliquis (apixaban), which is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy.

Preferred: BMYMP

Name: 
Bristol Myers Squibb Co.
Stock buyback: 
BMY buyback
Website: 
www.bms.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding BMY: 
125 (see which ones)
Total Market Value Held by ETFs: 
$14,887,798,101.87
Total Market Capitalization: 
$106,266,000,000
% of Market Cap. Held by ETFs: 
14.01%
Name:  Bristol Myers Squibb Co.
Stock buyback:  BMY buyback
Website:  www.bms.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding BMY:  125 (see which ones)
Total Market Value Held by ETFs:  $14,887,798,101.87
Total Market Capitalization:  $106,266,000,000
% of Market Cap. Held by ETFs:  14.01%

BMY Next Earnings Date »
BMY Next Dividend Date »
(Projection based upon history)
BMY Dividend Growth Rate »
Quotes delayed 20 minutes

Hold (2.30 out of 4)
6th percentile
(ranked lower than approx. 94% of all stocks covered)

Analysts' Target Price:
BMY Forecast

Based on data provided by Zacks Investment Research via Quandl.com

Forum posts »



 

BMY | Bristol Myers Squibb Co. | Dividend History | Dividend Channel | www.DividendChannel.com

Copyright © 2010 - 2024, All Rights Reserved Nothing in Dividend Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and dividend videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact Dividend Channel; Meet Our Editorial Staff.